LianBio reported a net loss of $24.0 million for the third quarter of 2023, compared to a net loss of $21.9 million for the third quarter of 2022. Research and development expenses were $9.0 million, and general and administrative expenses were $17.3 million. The company's cash, cash equivalents, and marketable securities totaled $252.2 million as of September 30, 2023. LianBio continues its strategic review.

LianBio reported a net loss of $21.6 million for the second quarter of 2023, compared to a net loss of $42.4 million for the second quarter of 2022. Research and development expenses decreased to $9.5 million from $28.6 million year-over-year, while general and administrative expenses increased slightly to $15.6 million from $14.6 million year-over-year. The company's cash, cash equivalents, and marketable securities totaled $267.3 million, providing a cash runway into the first half of 2025.

LianBio reported a net loss of $24.0 million for the first quarter of 2023, compared to a net loss of $27.7 million for the first quarter of 2022. The company's cash, cash equivalents, marketable securities and restricted cash totaled $286.6 million as of March 31, 2023, and is projected to fund operations through the end of 2024. The company is preparing for the commercial launch of mavacamten in China.

LianBio reported a net loss of $18.3 million for the fourth quarter of 2022, compared to a net loss of $21.2 million for the same period in 2021. The company's cash, cash equivalents, and marketable securities totaled $302.4 million, providing a cash runway through the end of 2024. Key milestones anticipated in 2023 include topline data from the Phase 3 EXPLORER-CN trial of mavacamten and the Phase 3 LIBRA trial of TP-03.

LianBio reported a net loss of $21.9 million for the third quarter of 2022, compared to a net loss of $13.1 million for the third quarter of 2021. The company's cash balance was $331.8 million at the end of the third quarter of 2022, which is expected to fund operations into the second half of 2024.

LianBio reported a net loss of $42.4 million for the second quarter of 2022, with research and development expenses at $28.6 million and general and administrative expenses at $14.6 million. The company's cash balance at the end of the quarter was $349.4 million, expected to fund operations into the second half of 2024. Key milestones included completing enrollment in the China Phase 3 trial of mavacamten and submitting NDAs for mavacamten in Singapore and infigratinib in Hong Kong.

LianBio reported a net loss of $27.7 million for the first quarter of 2022, with research and development expenses at $12.3 million and general and administrative expenses at $16.1 million. The company's cash balance totaled $389.1 million, projected to fund operations through mid-2024.

LianBio reported a net loss of $21.2 million for the fourth quarter of 2021. The company's cash balance totaled $403.2 million, which is projected to fund operations through 2023. Key milestones included the initiation of the Phase 3 EXPLORER-CN trial of mavacamten and the approval of infigratinib for cholangiocarcinoma patients in Hainan Province.